The 80th anniversary of von Willebrand's disease: History, management and research

Haemophilia

Volumn 12, Issue 6, 2006, Pages 563-572

  Federici, Augusto B ^a   Berntorp, E ^b   Lee, C A ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Basic and clinical research; Desmopressin; Von Willebrand factor; Von Willebrand factor concentrates; Von Willebrand's disease

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; DESMOPRESSIN; RECOMBINANT BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

BLEEDING; CLINICAL OBSERVATION; CLINICAL TRIAL; CORRELATION ANALYSIS; CRYOPRECIPITATION; DISEASE CARRIER; DISEASE MARKER; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; GENE REPLACEMENT THERAPY; GENETIC CODE; GENETIC SCREENING; GENOTYPE; HEMOPHILIA A; HISTORY OF MEDICINE; HOMEOSTASIS; HUMAN; LABORATORY TEST; LONG TERM CARE; MEDICAL RESEARCH; MEDICAL SOCIETY; NONHUMAN; PATHOPHYSIOLOGY; PEDIGREE ANALYSIS; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; VON WILLEBRAND DISEASE;

CLINICAL TRIALS; HISTORY, 20TH CENTURY; HUMANS; PEDIGREE; PORTRAITS; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 33750696330     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2006.01393.x     Document Type: Review

References (58)

1. Von Willebrand EA. Hereditar pseudoemophili. Fin Lakaresallsk Handl 1926; 68: 87-112 (English translation in Haemophilia 1999; 5: 223-31).
2. Nilsson IM, Blomback M, Blomback B. Von Willebrand disease in Sweden. Its pathogenesis and treatment. Acta Med Scand 1959; 164: 263-78.
3. Salzman EW. Measurement of platelet adhesiveness. A simple in vitro technique demonstrating an abnormality in VWD. J Lab Clin Med 1963; 62: 724-35.
4. Zimmerman TS, Ratnoff OD, Powell AE. Immunologic differentiation of classic hemophilia (factor VIII deficiency) and von Willebrand disease. J Clin Invest 1971; 50: 244-54.
5. Howard MA, Sawer RJ, Firkin BC. Ristocetin: A means of differentiating von Willebrand's disease into two groups. Blood 1973; 41: 687-90.
6. Weiss HJ, Hoyer LW, Rickles FR et al. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content. J Clin Invest 1973; 52: 2708-16.
7. Bouma BN, Wiegerinck Y, Sixma JJ et al. Immunological characterization of purified anti-haemophilic factor (factor VIII) which corrects abnormal platelet retention in von Willebrand's disease. Nat New Biol 1972; 236: 104-6.
8. Hoyer LW, De Ios S, Hoyer JR. Antihemophilic factor antigen. Localization in endothelial cells by immunofluorescent microscopy. J Clin Invest 1973; 52: 2737-44.
9. Jaffe EA, Hoyer LW, Nachman RL. Synthesis of von Willebrand factor by cultured human endothelial cells. Proc Natl Acad Sci U S A1974; 71: 1906-9.
10. Nachman R, Levine R, Haffe EA. Synthesis of factor VIII antigen by cultured guinea pig megakaryocytes. J Clin Invest 1977; 60: 914-21.
11. Sporn LA, Chavin SI, Marder VJ, Wagner DD. Biosynthesis of von Willebrand protein by human megakaryocytes. J Clin Invest 1985; 76: 1102-6.
12. Tschopp TP, Weiss HJ, Baumgartner HR. Decreased adhesion of platelet to subendothelium in von Willebrand disease. J Lab Clin Med 1974; 83: 296-30.
13. Holmberg L, Nilsson IM. Genetic variants of von Willebrand disease. Br Med J 1972; 3: 317-20.
14. Peake IR, Bloom AL, Giddings JC. Inherited variants of factor VIII-related protein in von Willebrand's disease. N Engl J Med 1974; 291: 113-7.
15. Meyer D, Jenkins CSP, Dreyfus M et al. Experimental model for von Willebrand's disease. Nature 1973; 243: 293-4.
16. Barbui T, Baudo F, Ciavarella N et al. for the Italian Working Group. Spectrum of von Willebrand's disease: A study of 100 cases. Br J Haematol 1977; 35: 101-12.
17. Ruggeri ZM, Zimmerman TS. Willebrand's disease. Characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets. J Clin Invest 1980; 65: 1318-25.
18. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand disease. Blood 1987; 69: 453-9.
19. Lynch DC, Zimmerman TS, Collins CJ et al. Molecular cloning of cDNA for human von Willebrand factor: Authentication by a new method. Cell 1985; 41: 49-56.
20. Ginsburg D, Handin RI, Bonthron DT et al. Human von Willebrand factor (VWF): Isolation of complementary DNA (cDNA) clones and chromosomal localization. Science 1985; 228: 1401-6.
21. Verweij CL, de Vries CJ, Distel B et al. Construction of cDNA coding for human von Willebrand factor using antibody probes for colony-screening and mapping of the chromosomal gene. Nucleic Acids Res 1985; 13: 4699-717.
22. Sadler JE, Shelton-Inloes BB, Sorace JM et al. Cloning and characterization of two cDNA coding for human von Willebrand factor. Proc Natl Acad Sci U S A 1985; 82: 6394-8.
23. Wagner DD, Marder VJ. Biosynthesis of Willebrand factor by human endothelial cells: Processing steps and intracellular localization. J Cell Biol 1984: 99: 2123-30.
24. Romani de Wit T, Van Mourik JA. Biosynthesis, processing and secretion of von Willebrand factor: Biological implications. Best Pract Res Clin Haematol 2001; 14: 241-55.
25. Ginsburg D. Molecular genetics of von Willebrand disease. Thromb Haemost 1999; 82: 585-91.
26. Meyer D, Fressinaud E, Hilbert L et al. Type 2 von Willebrand disease causing defective von Willebrand factor-dependent platelet function. Best Pract Res Clin Haematol 2001; 14: 349-64.
27. Mazurier C, Goudemand J, Hilbert L, Caron C, Fressinaud E, Meyer D. Type 2 N von Willebrand disease: Clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology. Best Pract Res Clin Haematol 2001; 14: 337-48.
28. Sadler JE. A revised classification of von Willebrand disease. Thromb Haemost 1994; 71: 520-23.
29. James PD, Notley C, Hegadorn C et al. The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study. Blood 2006; Aug 10. [Epub ahead of print].
30. Goodeve A, Eikenboom J, Castaman G et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). Blood 2006; Sep 19. [Epub ahead of print].
31. Federici AB, Rand JH, Bucciarelli P et al. Subcommittee on von Willebrand factor acquired von Willebrand syndrome: Data from an international registry. Thromb Haemost 2000; 84: 345-9.
32. Tosetto A, Rodeghiero F, Castaman G et.al. A quantitative analysis of bleeding symptoms in type 1 of von Willebrand disease: Results from a multicenter European Study (MCMDM-1VWD). J Thromb Haemost 2006; 4: 766-73.
33. Blombäck B, Blombäck M. Purification of human and bovine fibrinogen. Arkiv Kemi 1956; 10: 415-43.
34. Pool JG, Robinson J. Observations on plasma banking and transfusion procedures for haemophilic patients using a quantitative assay for antihaemophilic globulin (AHG). Br J Haematol 1959; 5: 24-30.
35. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. A new pharmacological approach to the management of hemophilia and von Willebrand disease. Lancet 1977; 1: 869-72.
36. Cash JD, Garder AMA, Da Costa J. The release of plasminogen activator and factor VIII by LVP, AVP, DDAVP, ATIII and OT in man. Br J Haematol 1974; 27: 363-4.
37. Mannucci PM, Ghirardini A. Desmopressin: Twenty years later. Thromb Haemost 1997; 78: 958.
38. Federici AB. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: Results from current studies and surveys. Blood Coagul Fibrinol 2005; 16: S17-21.
39. Berntorp E, Nilsson IM. Use of high-purity factor VIII concentrate (Hemate-P) in von Willebrand disease. Vox Sang 1989; 56: 212-7.
40. Mannucci PM, Chediak J, Hanna W et.al. for the Alphanate Study Group. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: A prospective, multicenter study. Blood 2002; 99: 450-6.
41. Menache D, Aronson DL, Darr F et al. Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): Estimation of the rate of factor VIIIC synthesis. Br J Haematol 1996; 94: 740-5.
42. Mannucci PM. Recommended protocol for the study of the ex vivo biological effects of virus-inactivated plasma concentrates in patients with von Willebrand disease. Thromb Haemost 1992; 68: 84-7.
43. Federici AB, Castaman G, Mannucci PM. Italian Association of Hemophilia Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia 2002; 8: 607-21.
44. Sadler JE, Mannucci PM, Berntorp E et.al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000; 84: 160-74.
45. Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med 2004; 351: 683-94.
46. Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost 2002; 88: 378-9.
47. Berntorp E, Petrini P. Long-term prophylaxis in von Willebrand disease. Blood Coagul Fibrinol 2005; 16: S23-6.
48. Federici AB, Gianniello F, Canciani MT, Mannucci PM. Secondary long-term prophylaxis in severe patients with von Willebrand disease: An Italian cohort study. Blood 2005; 106: 507a (abstract 1782).
49. Berntorp E, Abshire T, on behalf of the vWD PN Steering Committee. The von Willebrand disease prophylaxis network (vWD PN): Exploring a treatment concept. Thromb Res 2006; 118 (Suppl. 1): S19-22.
50. Furlan M, Robles R, Laemle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87: 4223-34.
51. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ions. Blood 1996; 87; 4235-44.
52. Ruggeri ZM. Von Willebrand factor. J Clin Invest 1997; 99: 559-64.
53. Thompson SG, Kienast J, Pyke SD et.al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332: 635-41.
54. Catto AJ, Carter AM, Barret JH et.al. Von Willebrand factor and factor VIII in acute cerebrovascular disease. Relationship to stroke subtype and mortality. Thromb Haemost 1997; 77: 1104-8.
55. Van der Meer IM, Brouwers GJ, Bulk S et.al. Genetic variability of von Willebrand factor and risk of coronary heart disease. The Rotterdam Study. Br J Haematol 2004; 124: 343-7.
56. Terraube V, Pendu R, Baruch D et.al. Increased metastatic potential of tumor cells in von Willebrand factor deficient mice. J Thromb Haemost 2006; 4: 519-26.
57. Pendu R, Terraube V, Christophe OD et.al. P-selectin glycoprotein 1 ligand (PSGL-1) and beta2-integrin cooperate in adhesion of leukocytes to von Willebrand factor. Blood 2006; Aug 22. [Epub ahead of print].
58. De Meyer SF, Vanhoorelbeke K, Chuah MK et.al. Phenotype correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor. Blood 2006; 107: 4728-36.